Affiliations: [a] Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
| [b] Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
| [c] Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA
| [d] Center for Clinical Studies, Washington University School of Medicine, St. Louis, MO, USA
| [e] Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
| [f] Department of Physical Therapy, Washington University School of Medicine, St. Louis, MO, USA
| [g] Department of Occupational Therapy, Washington University School of Medicine, St. Louis, MO, USA
Correspondence:
[*]
Correspondence to: Ganesh M. Babulal, 660 S. Euclid Ave., Campus Box 8111, St. Louis, MO, USA. Tel.: +1 952 334 8536; E-mail: [email protected].
Abstract: We examined whether driving behavior can predict preclinical Alzheimer’s disease (AD). Data from 131 cognitively normal older adults with cerebrospinal fluid (CSF) and/or positron emission tomography (PET) biomarkers were examined with naturalistic driving behavior. Receiver operating characteristic curves were used to predict the highest 10%, 25%, and 50% of values for CSF tau/Aβ42, ptau181/Aβ42, or amyloid PET. Six in vivo driving variables alone yielded area under the curves (AUC) from 0.64–0.82. Addition of age, Apolipoprotein ɛ4, and neuropsychological measures to the models improved the AUC (0.81 to 0.90). Driving can be used as novel neurobehavioral marker to identify presence of preclinical AD.
